Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Weight changes are common in aging and Alzheimer’s disease (AD) and post-mortem findings suggested a relation between lower body mass index (BMI) and increased AD brain pathology. In the current multicenter study, we tested whether lower BMI is associated with higher core AD brain pathology as assessed by cerebrospinal fluid (CSF) based biological markers of AD in 751 living subjects: 308 patients with AD, 296 subjects with amnestic mild cognitive impairment (MCI), and 147 elderly healthy controls (HC). Based upon a priori cutoff values on CSF concentration of total tau and beta-amyloid (Aβ1-42), subjects were binarized into a group with abnormal CSF biomarker signature (CSF+) and those without (CSF−). Results showed that BMI was significantly lower in the CSF+ when compared to the CSF− group (F = 27.7, df = 746, p < 0.001). There was no interaction between CSF signature and diagnosis or ApoE genotype. In conclusion, lower BMI is indicative of AD pathology as assessed with CSF-based biomarkers in demented and non-demented elderly subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Self-citationCerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationPrevalence of Dementia in the United States: The Aging, Demographics, and Memory Study
Plassman, B. L., Langa, K. M., Fisher, G. G., Heeringa, S. G., Weir, D. R., Ofstedal, M. B., Burke, J. R., Hurd, M. D., Potter, G. G., Rodgers, W. L., et al. (2007) · Neuroepidemiology · doi:10.1159/000109998 · Cited by 1,932 · cited 2×
“Alzheimer’s disease (AD) is the most common form of age-related dementia, accounting for about 60%–80% of all cases and shows a prevalence of 14% in people at the age of about 70 years in the United States (Plassman et al., 2007).”
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 6×
“The combination of such CSF biomarkers shows a superior accuracy for the detection of AD when compared with the use of single CSF measures alone (Hansson et al., 2006; Herukka et al., 2007; Vemuri et al., 2009).”
InfluentialSelf-citationKnopman, D. S., DeKosky, S. T., Cummings, J. L., Chui, H., Corey–Bloom, J., Relkin, N., Small, G. W., Miller, B., & Stevens, J. C. (2001) · Neurology · doi:10.1212/wnl.56.9.1143 · Cited by 1,410
Obesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291 · cited 2×
“Both lower and higher BMI have been associated with the development of AD, where especially during midlife, obesity or higher BMI have been associated with increased risk of AD (Fitzpatrick et al., 2009; Kivipelto et al., 2005; Whitmer et al., 2005).”
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 2×
“We hypothesized that lower BMI levels are associated with abnormal CSF biomarker pattern of AD pathology regardless of clinical manifestation of dementia symptoms (Blennow and Hampel, 2003).”
Self-citationInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study
Whitmer, R. A., Gunderson, E. P., Barrett-Connor, E., Quesenberry, C. P., & Yaffe, K. (2005) · BMJ · doi:10.1136/bmj.38446.466238.e0 · Cited by 1,090
Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives
Rolland, Y., Czerwinski, S., van Kan, G. A., Morley, J. E., Cesari, M., Onder, G., Woo, J., Baumgartner, R., Pillard, F., Boirie, Y., et al. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982704 · Cited by 1,071
Self-citation
Cited by
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Self-citationWeiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
“Further evidence that cognitive reserve buffers the effects of the disease comes from studies by Ewers et al [460] and Pillai et al [461].”
ResultInfluentialSelf-citationPichet Binette, A., Janelidze, S., Cullen, N., Dage, J. L., Bateman, R. J., Zetterberg, H., Blennow, K., Stomrud, E., Mattsson‐Carlgren, N., & Hansson, O. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12787 · Cited by 226
“On the other hand, associations with BMI might be due partly to blood volume diluting plasma biomarkers concentrations in the case of NfL but to general disease progression for other markers (i.e., a lower BMI in individuals with prodromal AD induced by the disease 33,35 ).”
Self-citationObesity, leptin, and Alzheimer's disease
Lee, E. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06274.x · Cited by 126
“Ewers et al.23 Multicenter cross-sectional study (308 AD, 296 MCI, 147 controls) Abnormal CSF biomarker signature (tau and -amyloid) is associated with lower BMI.”
BackgroundSong, M., & Fan, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098398 · Cited by 11
“Thus, clinical trials should consider BMI (Body Mass Index) and energy balance when designing their systems to understand the mechanism of energy imbalance associated with AD onset or progression [31,32].”
Background
Metadata
- Authors
- Ewers, M., Schmitz, S., Hansson, O., Walsh, C., Fitzpatrick, A., Bennett, D., Minthon, L., Trojanowski, J. Q., Shaw, L. M., Faluyi, Y. O., Vellas, B., Dubois, B., Blennow, K., Buerger, K., Teipel, S. J., Weiner, M., & Hampel, H.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2012-08
- Volume
- 33
- Issue
- 8
- Pages
- 1599-1608
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2147187737
- Cited by
- 65
- References
- 23
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.